Dazopride

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 4-amino-5-chloro-N-(1,2-diethylpyrazolidin-4-yl)-2-methoxybenzamide

| image = Dazopride.svg

| tradename =

| pregnancy_category =

| legal_status = Uncontrolled

| routes_of_administration = Oral

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 70181-03-2

| ATC_prefix = none

| ATC_suffix =

| PubChem = 54801

| ChemSpiderID = 49487

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = CV07VSP2G8

| C=15 | H=23 | Cl=1 | N=4 | O=2

}}

Dazopride (AHR-5531) is an antiemetic and gastroprokinetic agent of the benzamide class which was never marketed.{{cite journal | vauthors = Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB | title = Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy | journal = Cancer Chemotherapy and Pharmacology | volume = 31 | issue = 6 | pages = 442–444 | year = 1993 | pmid = 8453682 | doi = 10.1007/bf00685032 | s2cid = 23122385 }}{{cite journal | vauthors = Alphin RS, Proakis AG, Leonard CA, Smith WL, Dannenburg WN, Kinnier WJ, Johnson DN, Sancilio LF, Ward JW | display-authors = 6 | title = Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility | journal = Digestive Diseases and Sciences | volume = 31 | issue = 5 | pages = 524–529 | date = May 1986 | pmid = 3698769 | doi = 10.1007/bf01320319 | s2cid = 6571531 }}{{cite journal | vauthors = Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, Owera-Atepo JB, Simpson KM, Tan CC, Tattersall D | display-authors = 6 | title = The action of dazopride to enhance gastric emptying and block emesis | journal = Neuropharmacology | volume = 26 | issue = 7A | pages = 669–677 | date = July 1987 | pmid = 3114664 | doi = 10.1016/0028-3908(87)90227-9 | s2cid = 25143512 }}{{cite journal | vauthors = Costall B, Domeney AM, Naylor RJ, Tattersall FD | title = Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs | journal = Neuropharmacology | volume = 26 | issue = 9 | pages = 1321–1326 | date = September 1987 | pmid = 2890117 | doi = 10.1016/0028-3908(87)90094-3 | s2cid = 24621209 }}{{cite book | vauthors = Ganellin CR , Triggle DJ | title = Dictionary of Pharmacological Agents | publisher = Chapman & Hall/CRC | location = Boca Raton | year = 1996 | isbn = 0-412-46630-9 | url = https://books.google.com/books?id=DeX7jgInYFMC&q=dazopride&pg=RA1-PA572}} It acts as a 5-HT₃ receptor antagonist and 5-HT₄ receptor agonist.{{cite journal | vauthors = Villalón CM, den Boer MO, Heiligers JP, Saxena PR | title = Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig | journal = British Journal of Pharmacology | volume = 102 | issue = 1 | pages = 107–112 | date = January 1991 | pmid = 2043916 | pmc = 1917868 | doi = 10.1111/j.1476-5381.1991.tb12140.x }} In addition to its gastrointestinal effects, dazopride facilitates learning and memory in mice.{{cite book | vauthors = Montgomery SA, Halbreich U | title = Pharmacotherapy for mood, anxiety, and cognitive disorders | publisher = American Psychiatric Press | location = Washington, DC | year = 2000 | isbn = 0-88048-885-9 | url = https://books.google.com/books?id=lkmYfaO3RicC&q=dazopride%20memory&pg=RA1-PA547}}